COVID, Kadha and Urticaria

---

Original Article

Author Details : Shilpa Vinay Dastikop, Sushruth Kamoji, Gajanan A Pise, M N Patil, Shradha Gurudev*

Volume : 7, Issue : 1, Year : 2021

Article Page : 70-73

https://doi.org/10.18231/j.ijced.2021.013

Suggest article by email

Get Permission

---

Abstract

Background: In wake of COVID19 crisis and a dearth of promising medicine/ vaccine to combat the novel virus ‘Ayurveda’- the science of life, recommends immunity boosting ‘Khada’- decoction, to enhance and maintain the body’s natural defence system to safeguard self; which can lead to acute urticaria when used excessively.
Aim: To evaluate if Kadha consumption was related to the rising cases of urticaria.
Materials and Methods: Patients visiting Dermatology OPD at Belagavi Institute of Medical Sciences, Belagavi with complaints of developing urticaria between April to July 2020 were enrolled in the study after taking their due consent. History elicited and examination done. Patients were enquired specifically for consumption, frequency and duration of use of kadha along with most common ingredients used for its preparation. Drugs taken, if any were noted.
Results: Out of 64 patients reporting urticaria, a male preponderance (M: F = 1.9:1) was observed. Duration of onset of urticaria ranged from 30 mins to few days. Generalised involvement was seen in 44%(n=28); localised in the rest. None reported angioedema. Majority (n=55, 86%) gave history of consumption of kadha; with 22, 16 and 9 of them consuming khada once, twice and thrice daily, respectively. 8 consumed kadha in tea. Severity and frequency of symptoms were proportional to the amount of kadha consumed. Symptoms appeared faster in patients who consumed kadha more frequently or with tea.
Conclusion: Possibility of occurrence of urticarial lesions can be adversely related to kadha when used excessively.

Keywords: Covid19, Khada, Urticaria.

How to cite : Dastikop S V, Kamoji S , Pise G A, Patil M N, Gurudev S , COVID, Kadha and Urticaria. IP Indian J Clin Exp Dermatol 2021;7(1):70-73

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.